Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that whole genome sequencing can help determine which patients with a multiple myeloma precursor condition, called MGUS or smoldering myeloma, progress to full-blown cancer. With further validation, these findings could revolutionize how these patients are diagnosed and treated.
READ ARTICLE
Whole Genome Sequencing Offers New Diagnostic Insights for Multiple Myeloma Precursor Conditions https://t.co/qjV1Hlek3y Who will progress to active disease myeloma? Who won’t?
— Jim Omel (@IMFjimMYELOMA) March 26, 2021